Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Immunogenicity and Safety of Pentaxim in South African Infants
- Conditions
- DiphtheriaTetanusHaemophilus InfectionsPertussisPoliomyelitis
- Interventions
- Biological: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-04-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 212
- Registration Number
- NCT00254969
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand
- Conditions
- DiphtheriaTetanusPoliomyelitisHaemophilus InfectionsPertussis
- Interventions
- Biological: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 186
- Registration Number
- NCT00255021
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
- Conditions
- Haemophilus Influenzae Type BTetanusDiphtheriaPolioPertussis
- Interventions
- Biological: Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 387
- Registration Number
- NCT00254917
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia Followed by Optional Extension up to 1 Year
- Conditions
- Sleep Initiation and Maintenance DisordersInsomnia
- Interventions
- Drug: eplivanserin (SR46349)Drug: placebo
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-11-30
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1155
- Registration Number
- NCT00253903
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2008-11-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 460
- Registration Number
- NCT00253955
- Locations
- 🇻🇪
Sanofi-Aventis, Caracas, Venezuela
Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia
- Conditions
- Sleep Initiation and Maintenance DisordersInsomnia
- Interventions
- Drug: placeboDrug: Eplivanserin
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2016-03-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 967
- Registration Number
- NCT00253968
- Locations
- 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 476
- Registration Number
- NCT00252330
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
- Conditions
- Anxiety Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 360
- Registration Number
- NCT00252343
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 468
- Registration Number
- NCT00252356
- Locations
- 🇨🇦
Sanofi-Aventis Administrative Office, Laval, Canada
An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2008-12-23
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 465
- Registration Number
- NCT00250627
- Locations
- 🇵🇹
Sanofi-Aventis Administrative Office, Porto Salvo, Portugal